SemaxCognitive & Neuroprotective PeptideSafety Rating 8/10

TypeSynthetic heptapeptide (ACTH analog)
CAS80714-61-0
MW813.9 g/mol
AAs7
Primary research areaNootropic / cognitive research

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range200–900 mcg/day intranasal (0.1% solution; 1 drop ≈ 50 mcg)source ↗
AdministrationIntranasal drops
Half-life~15 minutes (parent peptide; effects last hours)
Safety8/10 · Approved in Russia/Ukraine
NCAA D1Not listed

Price Comparison

Compare vendors · per 10mg

27 vendors competing

VendorPrice$ / mgUpdated
Deus MedicalBest $/mgCOA on requestOut of stock$16.20$1.62Apr 17, 2026Buy →
Polar PeptidesCOA on request$57.59$1.92Apr 17, 2026Buy →
Biotech PeptidesCOA unknown$53.00$2.12May 14, 2026Buy →
Amino ClubCOA ✓ · 3P$23.99$29.99−20% · code PEPTIDEPRICES$2.40May 14, 2026Buy →
Swiss ChemsCOA ✓ · 3P$73.95$2.47Apr 17, 2026Buy →
$25 off $100+·auto

Overview

About Semax

Mechanism of action

Synthetic analogue of ACTH(4-7); increases BDNF and NGF expression; modulates dopaminergic and serotonergic systems; neuroprotective; enhances memory consolidation.

Safety profile

Very well-tolerated. Occasional nasal irritation, fatigue, or overstimulation. Mild dopaminergic effects. · Approved for neurological conditions in Russia; intranasal well-tolerated; no major safety signals

Storage

Stability & handling

❄️Lyophilized (powder)−20°Cprotect from light
💉Reconstituted2–8°Cwithin 4 weeks
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Safety & Interactions

Contraindications & Drug Interactions

Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.

ℹ NoteCaution

Russian clinical use for stroke/TBI. No significant contraindications reported but Western clinical data is limited.

Related pages

More on Semax

Stack & Compare

Frequently Researched Together

Learn More

Semax Guide

A research guide to Semax — the nootropic peptide developed in Russia.

Read full guide · 8 min read →

Research

Studies & key findings

  • ACTH(4-7)-Pro-Gly-Pro heptapeptide with nootropic and neuroprotective properties; approved in Russia for ischemic stroke and cognitive disorders, delivered intranasally.
  • Potently upregulates BDNF, TrkB, and NGF expression in rat hippocampus — the mechanistic basis for cognitive-enhancing and neuroprotective effects.

7 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch